Flag of the European Union EU Clinical Trials Register Help

Clinical trials for paclitaxel

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    890 result(s) found for: paclitaxel. Displaying page 33 of 45.
    «« First « Previous 29  30  31  32  33  34  35  36  37  Next» Last»»
    EudraCT Number: 2008-001032-12 Sponsor Protocol Number: PANTHERA Start Date*: 2008-10-28
    Sponsor Name:Universitätsklinikum Schleswig-Holstein
    Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer
    Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prohibited by CA)
    Trial results: (No results available)
    EudraCT Number: 2013-005590-41 Sponsor Protocol Number: M14REV Start Date*: 2015-02-10
    Sponsor Name:Netherlands Cancer Institute
    Full Title: A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated Her2 negative advanced breast cance...
    Medical condition: BRCA1 or -2 mutated breast cancer Any other cancer type expected to benefit from olaparib-carboplatin
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000713-11 Sponsor Protocol Number: CV149-208 Start Date*: 2007-07-20
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers i...
    Medical condition: Biomarkers of inflammation and platelet activation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058542 Anti-platelet antibody LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003064-50 Sponsor Protocol Number: HLX10-004-NSCLC303 Start Date*: 2020-06-17
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin-Nanoparticle Albumin-Bound (na...
    Medical condition: First-Line Therapy for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002565-22 Sponsor Protocol Number: LOKON002 Start Date*: 2017-12-21
    Sponsor Name:Lokon Pharma AB
    Full Title: Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
    Medical condition: Colorectal, ovarian, pancreatic, gallbladder and bile duct cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003304-43 Sponsor Protocol Number: INCB24360-309 Start Date*: 2018-04-12
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat with Platinum Doublet Chemotherapy versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small C...
    Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004482-89 Sponsor Protocol Number: GBG93 Start Date*: 2018-01-08
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE IV STUDY EVALUATING PALBOCICLIB PLUS ENDOCRINE TREATMENT VERSUS A CHEMOTHERAPY-BASED TREATMENT STRATEGY IN PATIENTS WITH HORMONE RECEPTOR POSITIVE / HER...
    Medical condition: Metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002249-22 Sponsor Protocol Number: D-V Start Date*: 2015-07-15
    Sponsor Name:Universitätsklinikum Ulm (AöR)
    Full Title: DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pert...
    Medical condition: Patients with HER2-positive and hormone-receptor positive metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004340-11 Sponsor Protocol Number: 17403 Start Date*: 2018-06-13
    Sponsor Name:Bayer AG
    Full Title: A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or me...
    Medical condition: mRNA FGF receptor 1 and 3 positive locally advanced or metastatic urothelial carcinoma progressed after prior platinum-containing chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Prematurely Ended) FR (Completed) AT (Completed) CZ (Completed) ES (Completed) PT (Completed) FI (Completed) SK (Completed) HU (Completed) DK (Completed) BE (Completed) SE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000562-36 Sponsor Protocol Number: BIG2-06/N063D/EGF106708 Start Date*: 2007-05-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their comb...
    Medical condition: Operable primary breast cancer with over expression/ amplification of HER2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) HU (Completed) FR (Completed) GB (Completed) SK (Completed) EE (Completed) CZ (Completed) DK (Completed) BE (Completed) DE (Completed) GR (Completed) NL (Completed) IT (Completed) ES (Completed) SI (Completed) BG (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003536-21 Sponsor Protocol Number: CA209-816 Start Date*: 2017-03-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
    Medical condition: Early Stage Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Completed) FR (Trial now transitioned) GR (Completed) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005745-20 Sponsor Protocol Number: IPR/26 Start Date*: 2013-03-24
    Sponsor Name:MolMed S.p.A.
    Full Title: NGR018: Randomized phase II study of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancer
    Medical condition: Advanced or metastatic platinum-resistant ovarian cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001472-10 Sponsor Protocol Number: INCB24360-210 Start Date*: 2012-10-19
    Sponsor Name:Incyte Corporation
    Full Title: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FAL...
    Medical condition: BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001755-45 Sponsor Protocol Number: OX4325 Start Date*: 2016-09-12
    Sponsor Name:Mateon Therapeutics, Inc.
    Full Title: FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bev...
    Medical condition: Platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013472-41 Sponsor Protocol Number: GOIRC01/2009 Start Date*: 2009-08-03
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: A GOIRC Phase II randomized trial of an oral chemotherapy combination of Capecitabine plus Vinorelbine and their sequential single agent use in Metastatic Breast Cancer
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004499-38 Sponsor Protocol Number: CCR 3116 Start Date*: 2010-04-16
    Sponsor Name:Royal Marsden NHS Foundation Trust
    Full Title: A randomised double-blind placebo-controlled trial of the safety and efficacy of ethosuximide 250mg capsules for the management of chemotherapy-induced painful peripheral neuropathy.
    Medical condition: The medicial condition under investigation is chemotherapy-induced painful peripheral neuropathy (CIPPN). CIPPN is a complication of several classes of chemotherapy agents e.g taxanes (paclitaxel, ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036109 Polyneuropathy due to drugs LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005096-85 Sponsor Protocol Number: XM22-ONC-40041 Start Date*: 2015-05-25
    Sponsor Name:Merckle GmbH
    Full Title: Safety and Efficacy of LONQUEX® (Lipegfilgrastim) in Comparison to Pegfilgrastim (Neulasta®, Amgen Inc.) and Placebo in Patients with Non-Small-Cell Lung Cancer Receiving First-Line Chemotherapy
    Medical condition: Advanced squamous or non-squamous non-small-cell lung cancer (NSCLC) Stage IIIB/IV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) LV (Completed) PL (Prematurely Ended) GR (Completed) BG (Completed) ES (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005605-36 Sponsor Protocol Number: SCI-Ta1-NSCLC-CHEMOP2-001 Start Date*: 2016-07-07
    Sponsor Name:SCICLONE PHARMACEUTICALS ITALY S.R.L.
    Full Title: Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type
    Medical condition: metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064049 Lung adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001218-26 Sponsor Protocol Number: TRO19622 CL E Q 1204-1 Start Date*: 2008-06-19
    Sponsor Name:TROPHOS SA
    Full Title: A double blind, placebo controlled study of the effect of 330mg QD of TRO19622 in the treatment of Chemotherapy Induced Peripheral Neuropathy.
    Medical condition: Symptoms of chemotherapy induced peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036109 Polyneuropathy due to drugs LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-001185-32 Sponsor Protocol Number: 38/2007/O/Sper Start Date*: 2007-03-28
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Protocol for the experimental study about Peritonectomy (CCR) associated with Chemo-Hyperthermic intra-peritonel (CHIP) treatment for primary or secondary peritoneal neoplastic desease (Peritoneal ...
    Medical condition: Peritoneal Carcinosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 29  30  31  32  33  34  35  36  37  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 14:18:06 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA